A5055330431- MicroRNA in disease regulation
- Lung Cancer Research Studies
- Circular RNAs in diseases
- Acute Lymphoblastic Leukemia research
- Heart Rate Variability and Autonomic Control
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Bladder and Urothelial Cancer Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Cardiovascular Syncope and Autonomic Disorders
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Chemotherapy-induced cardiotoxicity and mitigation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- RNA Interference and Gene Delivery
- Cancer-related molecular mechanisms research
- Sarcoidosis and Beryllium Toxicity Research
Penn State Milton S. Hershey Medical Center
2024-2025
Universidad de Guadalajara
2023-2024
Mexican Social Security Institute
2024
Pennsylvania State University
2024
Bladder cancer (BC) is one of the most common types worldwide, with significant differences in survival depending on degree muscle and surrounding tissue invasion. For this reason, timely detection monitoring disease are important. Surveillance cystoscopy an invasive, costly, uncomfortable procedure to monitor BC, raising need for new, less invasive alternatives. In scenario, microRNAs (miRNAs) represent attractive prognostic tools given their role as gene regulators different biological...
Abstract Background The role of adjuvant chemotherapy in early-stage small cell lung cancer (SCLC) and large neuroendocrine carcinoma (LCNEC) remains unclear, particularly for tumors. This study assesses the survival benefits after surgical resection with a novel focus on tumors less than 1 cm. Materials methods Data from National Cancer Database (NCDB) was extracted patients SCLC (n = 11,962) LCNEC 6821) who underwent between 2004 2020. Exclusion criteria were limited (< 30 days),...
Currently, the established approach for addressing stage IV non-small cell lung cancer (NSCLC) involves combining chemotherapy with immunotherapy. However, necessity molecular analysis prior to commencing immunotherapy often results in a delay its initiation following commencement of chemotherapy. Therefore, this study aimed significance postponing on pertinent patient outcomes.
Despite the improvement in survival acute lymphoblastic leukemia (ALL), there are still cases with evasion of chemotherapy-induced apoptosis. The IKK/NF-κB signaling pathway contributes to antiapoptotic gene expression. Pentoxifylline (PTX) inhibits IkB phosphorylation, blocking NF-κB and activity.